Cost-Effectiveness Analysis of Efgartigimod vs Chronic Immunoglobulin for the Treatment of Myasthenia Gravis in Canada
Efgartigimod provides greater benefit in terms of lower costs than chronic immunoglobulins for AChR-Ab+ gMG patients in Canada.
Authors
- David Garcia (ORCID: https://orcid.org/0000-0003-2097-1675)
- Angela Genge (ORCID: https://orcid.org/0000-0001-5587-9946)
- Roger Kaprielian
- Jason Locklin (ORCID: https://orcid.org/0000-0001-9272-2403)
- Cynthia Z. Qi
- Zaeem A. Siddiqi (ORCID: https://orcid.org/0000-0003-2421-8381)
- Tom Hughes
- Allen Zhou (ORCID: https://orcid.org/0009-0004-9862-8492)
Institutions
- University of Alberta (CA)
- EVERSANA (Canada) (CA)
- Argenx (Belgium) (BE)
- McGill University (CA)
Publication Details
- Journal
- Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- Published
- 2025-10-27
- DOI
- https://doi.org/10.1017/cjn.2025.10449
- Citations
- 2
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 2.78